• Something wrong with this record ?

MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma

Y. Mytsyk, V. Dosenko, Y. Borys, A. Kucher, K. Gazdikova, D. Busselberg, M. Caprnda, P. Kruzliak, AA. Farooqi, M. Lubov,

. 2018 ; 50 (5) : 851-859. [pub] 20180316

Language English Country Netherlands

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc19000863
E-resources Online Full text

NLK ProQuest Central from 1999-01-01 to 1 year ago
Medline Complete (EBSCOhost) from 2011-03-01 to 1 year ago
Health & Medicine (ProQuest) from 1999-01-01 to 1 year ago

Links

PubMed 29549624
DOI 10.1007/s11255-018-1841-x
Knihovny.cz E-resources

INTRODUCTION: Currently, there is no accurate diagnostic molecular biomarker for renal cell carcinoma (RCC). The aim of this study was to assess the expression of microRNA-15a (miR-15a) in urine of patients with RCC and to evaluate its potential as a diagnostic molecular biomarker. MATERIALS AND METHODS: In total, 67 patients with solid renal tumors were enrolled: clear-cell RCC (ccRCC, n = 22), papillary RCC (pRCC, n = 16), chromophobe RCC (chRCC, n = 14), oncocytoma (n = 8), papillary adenoma (n = 2) and angiomyolipoma (n = 5). MiRNA-15a expression levels measurement in urine were performed using qPCR. Urine of 15 healthy volunteers without kidney pathology was used as control. RESULTS: We observed a difference in mean miR-15a expression values in groups of pre-operative patients with RCC, benign renal tumors and healthy persons (2.50E-01 ± 2.72E-01 vs 1.32E-03 ± 3.90E-03 vs 3.36E-07 ± 1.04E-07 RFU, respectively, p < 0.01). There was no difference in miR-15a expression between ccRCC, pRCC and chRCC (p > 0.05). Direct association between RCC size and miR-15a expression values was obtained (Pearson correlation coefficient-0.873). On the 8th day after nephrectomy, mean expression value in patients with RCC decreased by 99.53% (p < 0.01). MiR-15a expression differentiated RCC from benign renal tumors with 98.1% specificity, 100% sensitivity at a cut-off value of 5.00E-06 RFU, with AUC-0.955. CONCLUSIONS: MiR-15a expression measured in urine may be used as diagnostic molecular biomarker for RCC.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19000863
003      
CZ-PrNML
005      
20190121103331.0
007      
ta
008      
190107s2018 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s11255-018-1841-x $2 doi
035    __
$a (PubMed)29549624
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Mytsyk, Yulian $u Department of Urology, Danylo Halytsky Lviv National Medical University, Pekarska Str. 69, Lviv, Ukraine. mytsyk.yulian@gmail.com.
245    10
$a MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma / $c Y. Mytsyk, V. Dosenko, Y. Borys, A. Kucher, K. Gazdikova, D. Busselberg, M. Caprnda, P. Kruzliak, AA. Farooqi, M. Lubov,
520    9_
$a INTRODUCTION: Currently, there is no accurate diagnostic molecular biomarker for renal cell carcinoma (RCC). The aim of this study was to assess the expression of microRNA-15a (miR-15a) in urine of patients with RCC and to evaluate its potential as a diagnostic molecular biomarker. MATERIALS AND METHODS: In total, 67 patients with solid renal tumors were enrolled: clear-cell RCC (ccRCC, n = 22), papillary RCC (pRCC, n = 16), chromophobe RCC (chRCC, n = 14), oncocytoma (n = 8), papillary adenoma (n = 2) and angiomyolipoma (n = 5). MiRNA-15a expression levels measurement in urine were performed using qPCR. Urine of 15 healthy volunteers without kidney pathology was used as control. RESULTS: We observed a difference in mean miR-15a expression values in groups of pre-operative patients with RCC, benign renal tumors and healthy persons (2.50E-01 ± 2.72E-01 vs 1.32E-03 ± 3.90E-03 vs 3.36E-07 ± 1.04E-07 RFU, respectively, p < 0.01). There was no difference in miR-15a expression between ccRCC, pRCC and chRCC (p > 0.05). Direct association between RCC size and miR-15a expression values was obtained (Pearson correlation coefficient-0.873). On the 8th day after nephrectomy, mean expression value in patients with RCC decreased by 99.53% (p < 0.01). MiR-15a expression differentiated RCC from benign renal tumors with 98.1% specificity, 100% sensitivity at a cut-off value of 5.00E-06 RFU, with AUC-0.955. CONCLUSIONS: MiR-15a expression measured in urine may be used as diagnostic molecular biomarker for RCC.
650    _2
$a adenom $x moč $7 D000236
650    _2
$a oxyfilní adenom $x moč $7 D018249
650    _2
$a senioři $7 D000368
650    _2
$a angiomyolipom $x moč $7 D018207
650    _2
$a nádorové biomarkery $x moč $7 D014408
650    _2
$a karcinom z renálních buněk $x diagnóza $x patologie $x chirurgie $x moč $7 D002292
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a nádory ledvin $x diagnóza $x patologie $x chirurgie $x moč $7 D007680
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mikro RNA $x moč $7 D035683
650    _2
$a lidé středního věku $7 D008875
650    _2
$a staging nádorů $7 D009367
650    _2
$a nefrektomie $7 D009392
650    _2
$a polymerázová řetězová reakce $7 D016133
650    _2
$a senzitivita a specificita $7 D012680
650    _2
$a tumor burden $7 D047368
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dosenko, Victor $u Department of General and Molecular Pathophysiology, Bogomoletz Institute of Physiology, National Academy of Sciences of Ukraine, Kiev, Ukraine.
700    1_
$a Borys, Yuriy $u Department of Urology, Danylo Halytsky Lviv National Medical University, Pekarska Str. 69, Lviv, Ukraine.
700    1_
$a Kucher, Askold $u Department of Radiology, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
700    1_
$a Gazdikova, Katarina $u Department of Nutrition, Faculty of Nursing and Professional Health Studies, Slovak Medical University, Limbova 12, 833 03, Bratislava, Slovak Republic. katarina.gazdikova@szu.sk. Department of General Medicine, Faculty of Medicine, Slovak Medical University, Bratislava, Slovak Republic. katarina.gazdikova@szu.sk.
700    1_
$a Busselberg, Dietrich $u Weill Cornell Medical College in Qatar, Qatar Foundation, Education City, Doha, Qatar.
700    1_
$a Caprnda, Martin $u 1st Department of Internal Medicine, Faculty of Medicine, Comenius University and University Hospital, Bratislava, Slovakia.
700    1_
$a Kruzliak, Peter $u Department of Internal Medicine, Brothers of Mercy Hospital, Brno, Czech Republic. kruzliakpeter@gmail.com. Research and Development Services, Brno, Czech Republic. kruzliakpeter@gmail.com. 2nd Department of Surgery, Faculty of Medicine, Masaryk University and St. Anne's University Hospital, Pekarska 664/53, 656 91, Brno, Czech Republic. kruzliakpeter@gmail.com.
700    1_
$a Farooqi, Ammad Ahmad $u Laboratory for Translational Oncology and Personalized Medicine, Rashid Latif Medical College, Lahore, Pakistan.
700    1_
$a Lubov, Manyuk $u Department of Foreign Languages, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
773    0_
$w MED00002396 $t International urology and nephrology $x 1573-2584 $g Roč. 50, č. 5 (2018), s. 851-859
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29549624 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20190121103550 $b ABA008
999    __
$a ok $b bmc $g 1364853 $s 1038986
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 50 $c 5 $d 851-859 $e 20180316 $i 1573-2584 $m International urology and nephrology $n Int Urol Nephrol $x MED00002396
LZP    __
$a Pubmed-20190107

Find record

Citation metrics

Archiving options